CMS Open Payments · Program Year 2024
Ultradent Products Inc
Ultradent Products Inc reported $13,443,906.11 across General Payments, Research, and Ownership to 17,574 physicians and teaching hospitals across 17,576 transactions.
- $13.4M Top 10% payer
- All-tracks total
- 17,576 Top 10% volume
- Transactions
- 17,574 Top 10% reach
- Recipients
- −$160.3K
- General Payments vs PY2023
Ultradent Products Inc reported $13,443,906.11 across all CMS Open Payments tracks (General + Research + Ownership) to 17,574 physicians and teaching hospitals in Program Year 2024 - ranking #138 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $1,812,161.11, averaging $764.99 per recipient.
How Ultradent Products Inc's $13.4M all-tracks total breaks down
Ultradent Products Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
91/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ultradent-products-inc Ultradent Products Inc
$13.4M · #138/1,925 · 0.1% industry · PY2024
- TOT $13.4M
- RANK #138
- SHARE 0.1%
- TXN 17,576
- RCP 17,574
- CAT 5
- GEN $1.8M
- ΔGEN −$160.3K
- TOP1 2.6%
- PY 2024
Volume peers
Nearest volume peer: BeiGene USA, Inc. ($13.4M)
Ultradent Products Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Ultradent Products Inc's CMS-reported General Payments decreased by $160.3K (−8.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ULTRADENT PRODUCTS INCPY2023: ULTRADENT PRODUCTS INCPY2024: Ultradent Products Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,972,439.62
- PY2024
- $1,812,161.11
What the Data Shows for Ultradent Products Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Ultradent Products Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 5 general-payment categories charted below, "Gift" is the largest at $1.4M across 10,796 transactions, 76.1% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 5 types of general payments, Ultradent Products Inc's largest category was "Gift" at $1.4M - 76.1% of General Payments.
Ultradent Products Inc reports 5 general-payment categories - the top three are Gift (76.1%), Honoraria (13.2%), and Food and Beverage (8.2%). The remaining 2 categories make up 2.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Ultradent Products Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Gift | $1.4M | 10,796 | 76.1% |
| Honoraria | $239.6K | 72 | 13.2% |
| Food and Beverage | $148.0K | 6,608 | 8.2% |
| Travel and Lodging | $45.4K | 89 | 2.5% |
| Entertainment | $58.92 | 9 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $195,543.68 (10.8%) of $1,812,161.11 in this company's General Payments records across 10,904 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Ultradent Products Inc
The five named recipients with the highest reported General Payments from this company
- 1
Marc Geissberger
$46,957.95 across 19 reported transactions
- 2
Ron Kaminer
$38,324.27 across 16 reported transactions
- 3
E Chipian
$37,774.62 across 53 reported transactions
- 4
William Behlke
$37,287.44 across 31 reported transactions
- 5
Susan Mcmahon
$35,199.40 across 14 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Ultradent Products Inc ranks #138 of 1,925 by total payments (top 7% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,786 of 1,838 by HHI (bottom 3% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Supernus Pharmaceuticals, Inc. : $4.4M total payments, HHI 42
- Ethicon US, LLC : $1.6M total payments, HHI 41
- Pylant Medical : $104.7K total payments, HHI 40
- Teva Pharmaceuticals USA, Inc. : $13.9M total payments, HHI 40
- American Orthodontics Corporation : $374.7K total payments, HHI 38
- Impel Pharmaceuticals LLC : $15.8K total payments, HHI 36
- Ultradent Products Inc (this company) : $1.8M total payments, HHI 36
- OWP Pharmaceuticals, Inc. : $7.8K total payments, HHI 35
- Dilon Technologies, Inc. : $148.5K total payments, HHI 35
- Boehringer Ingelheim Pharmaceuticals, Inc. : $17.9M total payments, HHI 34
- Inspire Medical Systems, Inc. : $3.9M total payments, HHI 34
- Hologic Sales and Service, LLC : $1.2M total payments, HHI 33
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Ultradent Products Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ultradent Products Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Ultradent Products Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Blueprint Medicines Corporation
Alcon Vision LLC
Centinel Spine, LLC
Lazurite Inc.
Atricure, Inc.
Put this to use
Ultradent Products Inc ranks #138 of 1,925 by all-tracks total payments, led by "Gift".
- See where Ultradent Products Inc sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Gift" spend across every manufacturer, not just Ultradent Products Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.